lovastatin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperlipidaemic substances, HMG CoA reductase inhibitors 1612 75330-75-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lovastatin
  • lostatin
  • mevacor
A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.
  • Molecular weight: 404.55
  • Formula: C24H36O5
  • CLOGP: 4.08
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 72.83
  • ALOGS: -4.22
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
45 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.29 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 5 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Aug. 31, 1987 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myalgia 47.16 12.34 132 18641 122956 46544333
Rhabdomyolysis 45.19 12.34 69 18704 41840 46625449
Rheumatoid arthritis 42.19 12.34 22 18751 240193 46427096
Cardiac failure congestive 40.79 12.34 104 18669 91646 46575643
Blood glucose increased 35.57 12.34 85 18688 71928 46595361
Drug hypersensitivity 35.32 12.34 192 18581 243633 46423656
Atrial fibrillation 30.21 12.34 101 18672 103489 46563800
Coronary artery disease 27.51 12.34 49 18724 33703 46633586
Myopathy 27.23 12.34 25 18748 8856 46658433
Amyotrophic lateral sclerosis 25.16 12.34 11 18762 1052 46666237
Muscle spasms 24.30 12.34 106 18667 123007 46544282
Myocardial infarction 24.05 12.34 90 18683 97438 46569851
Exposure during pregnancy 23.76 12.34 7 18766 108205 46559084
Pyrexia 20.37 12.34 72 18701 348730 46318559
Retroperitoneal oedema 19.80 12.34 4 18769 22 46667267
Febrile neutropenia 19.23 12.34 7 18766 94620 46572669
Treatment failure 18.72 12.34 7 18766 93080 46574209
Off label use 18.05 12.34 85 18688 379756 46287533
General physical health deterioration 15.76 12.34 14 18759 115755 46551534
Asthenia 15.48 12.34 192 18581 310883 46356406
Intentional overdose 14.62 12.34 4 18769 64940 46602349
C-reactive protein increased 14.39 12.34 3 18770 58587 46608702
Cerebrovascular accident 14.20 12.34 79 18694 100960 46566329
Product use in unapproved indication 13.43 12.34 10 18763 90263 46577026
Synovitis 13.31 12.34 4 18769 61071 46606218
Dehydration 12.99 12.34 109 18664 159431 46507858
Fatigue 12.96 12.34 328 18445 608369 46058920
Infusion related reaction 12.88 12.34 13 18760 101195 46566094
Interstitial lung disease 12.77 12.34 3 18770 53946 46613343
Chest pain 12.56 12.34 117 18656 176207 46491082
Chronic obstructive pulmonary disease 12.42 12.34 51 18722 57582 46609707

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 48.11 13.02 98 14048 63482 29874850
Myasthenic syndrome 39.29 13.02 12 14134 347 29937985
Cardiac failure congestive 34.78 13.02 103 14043 84304 29854028
Myalgia 33.94 13.02 96 14050 76571 29861761
Neck mass 29.45 13.02 14 14132 1381 29936951
Drug abuse 25.72 13.02 4 14142 82068 29856264
Diverticulum 25.70 13.02 23 14123 6710 29931622
Blood creatine phosphokinase increased 20.46 13.02 56 14090 43792 29894540
Sleep inertia 20.20 13.02 4 14142 16 29938316
Hand deformity 20.18 13.02 12 14134 1861 29936471
Back disorder 20.01 13.02 19 14127 5975 29932357
Asthenia 19.90 13.02 175 13971 221115 29717217
Febrile neutropenia 19.83 13.02 13 14133 106680 29831652
Chondrodystrophy 18.86 13.02 4 14142 24 29938308
Pyrexia 18.54 13.02 74 14072 294415 29643917
Coronary artery disease 17.97 13.02 58 14088 49654 29888678
Thrombocytosis 17.88 13.02 14 14132 3399 29934933
Myopathy 17.11 13.02 23 14123 10563 29927769
International normalised ratio increased 16.63 13.02 55 14091 47684 29890648
Anxiety 16.54 13.02 85 14061 89786 29848546
Injury 15.82 13.02 33 14113 21698 29916634
Pinguecula 14.29 13.02 3 14143 17 29938315
Gross motor delay 13.85 13.02 5 14141 245 29938087
Cardiovascular disorder 13.61 13.02 21 14125 10931 29927401

Pharmacologic Action:

SourceCodeDescription
ATC C10AA02 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
HMG CoA reductase inhibitors
ATC C10BA01 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
Combinations of various lipid modifying agents
FDA MoA N0000000121 Hydroxymethylglutaryl-CoA Reductase Inhibitors
FDA EPC N0000175589 HMG-CoA Reductase Inhibitor
MeSH PA D000924 Anticholesteremic Agents
MeSH PA D000963 Antimetabolites
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D057847 Lipid Regulating Agents
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:35821 hypocholesteremic agent
CHEBI has role CHEBI:50266 prodrugs
CHEBI has role CHEBI:76956 aspergillus metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Hyperlipidemia indication 55822004 DOID:1168
Arteriosclerotic vascular disease indication 72092001
Hypoalphalipoproteinemia indication 190785000
Familial hypercholesterolemia - heterozygous indication 238079002
Mixed hyperlipidemia indication 267434003
Hypertriglyceridemia indication 302870006
Myocardial Reinfarction Prevention indication
Slow Progression of Coronary Artery Disease indication
Primary Prevention of Coronary Heart Disease indication
Myocardial Infarction Prevention indication
Cerebrovascular accident off-label use 230690007
Prevention of Transient Ischemic Attacks off-label use
Hypophosphatemia contraindication 4996001
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Myocardial infarction contraindication 22298006 DOID:5844
Low blood pressure contraindication 45007003
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Gout contraindication 90560007 DOID:13189
Disorder of muscle contraindication 129565002 DOID:423
Liver function tests abnormal contraindication 166603001
Hemorrhagic cerebral infarction contraindication 230706003
Arterial hemorrhage contraindication 234003006
Disease of liver contraindication 235856003 DOID:409
Rhabdomyolysis contraindication 240131006
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Surgical procedure contraindication 387713003
Acute coronary syndrome contraindication 394659003
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Traumatic injury contraindication 417746004
Uncontrolled Epilepsy contraindication

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme INHIBITOR IC50 7.67 WOMBAT-PK CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.06 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.10 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 4.81 DRUG MATRIX
Substance-K receptor GPCR Ki 5.03 DRUG MATRIX
Hydroxycarboxylic acid receptor 2 GPCR IC50 7.30 WOMBAT-PK
Hydroxycarboxylic acid receptor 3 GPCR IC50 6.53 WOMBAT-PK
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor AGONIST EC50 6 IUPHAR
Histone deacetylase 6 Enzyme IC50 4.79 CHEMBL
Leukocyte adhesion glycoprotein LFA-1 alpha Adhesion Kd 4.89 CHEMBL
Histone deacetylase 1 Enzyme IC50 4.92 CHEMBL
Histone deacetylase 2 Enzyme IC50 4.59 CHEMBL
Androgen receptor Transcription factor Ki 4.70 DRUG MATRIX
Acetylcholinesterase Enzyme Ki 5.57 CHEMBL
Cholinesterase Enzyme Ki 5.96 CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme IC50 8.52 CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme IC50 7.57 CHEMBL
Acyl-CoA:cholesterol acyltransferase Unclassified IC50 4.77 CHEMBL

External reference:

IDSource
4019482 VUID
N0000147602 NUI
D00359 KEGG_DRUG
4019482 VANDF
C0024027 UMLSCUI
CHEBI:40303 CHEBI
803 PDB_CHEM_ID
CHEMBL503 ChEMBL_ID
D008148 MESH_DESCRIPTOR_UI
DB00227 DRUGBANK_ID
2739 IUPHAR_LIGAND_ID
6074 INN_ID
9LHU78OQFD UNII
53232 PUBCHEM_CID
224938 RXNORM
1105 MMSL
42628 MMSL
4998 MMSL
d00280 MMSL
002063 NDDF
386024001 SNOMEDCT_US
96303004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0093-0576 TABLET 20 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0093-0926 TABLET 10 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0093-0928 TABLET 40 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0070 TABLET 10 mg ORAL ANDA 18 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0072 TABLET 20 mg ORAL ANDA 18 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0074 TABLET 40 mg ORAL ANDA 18 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-5589 TABLET 20 mg ORAL ANDA 20 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-6551 TABLET 40 mg ORAL ANDA 20 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-6590 TABLET 10 mg ORAL ANDA 20 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-7674 TABLET 10 mg ORAL ANDA 21 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-7679 TABLET 20 mg ORAL ANDA 21 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-7685 TABLET 40 mg ORAL ANDA 20 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-7690 TABLET 40 mg ORAL ANDA 21 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-8151 TABLET 20 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-8152 TABLET 40 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 10544-235 TABLET 10 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 10544-241 TABLET 20 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 10544-242 TABLET 40 mg ORAL ANDA 22 sections
Lovastatin Human Prescription Drug Label 1 10544-246 TABLET 20 mg ORAL ANDA 19 sections
LOVASTATIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-311 TABLET 10 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 21695-534 TABLET 10 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 21695-535 TABLET 20 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 21695-536 TABLET 40 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 33261-547 TABLET 10 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 33261-548 TABLET 20 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 33261-549 TABLET 40 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 42254-025 TABLET 40 mg ORAL ANDA 21 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 42254-028 TABLET 20 mg ORAL ANDA 21 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 42254-106 TABLET 10 mg ORAL ANDA 21 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 43063-493 TABLET 10 mg ORAL ANDA 12 sections